Who is eligible for clinical trial NCT02682147?

Participants must meet protocol criteria for Emphysema. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT02682147 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-04-10

Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema (NCT02682147)

🔵 Active, Not Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: Eric A. Hoffman

🩺 Plain-English Summary (8th-Grade Level)

This study will use dual energy x-ray computed tomography (DECT) to evaluate the relationship between heterogeneous perfusion, hypoxia (low oxygen in inspired gas) and induction of pulmonary vascular dilatation to characterize emphysema susceptibility in a normal smoking population. The investigators will correlate DECT measures of perfusion with lung injury measured by single photon emission computed tomography (SPECT). The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (13 items).

Location: University of Iowa — Iowa City, Iowa

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Must be between the ages of 25 and 65.
Must be currently smoking at least 1/2 pack/day (confirmed with cotinine level).
Must have pulmonary function test (PFT) results that meet the following (there will be two groups): Group 1:
Forced expiratory volume at one second (FEV1)/Forced vital capacity (FVC) \> 70%
Forced Expiratory Flow at 25-75% of predicted(FEF25-75) \> 79% of predicted
FVC greater than 80% of predicted Group 2: For subjects with mild lung impairment:
FEV1\>80% of predicted
FEV1/FVC\<0.7
Must be able to give informed consent for self.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Pregnant or breastfeeding females.
Body Mass Index (BMI) greater than 32.
Weight of greater than 220 pounds (100 kg).
Allergies to shell fish, seafood, eggs or iodine.
Heart disease, kidney disease or diabetes.
Diagnosis of asthma.
Usage of any medications that are known to affect the heart or lungs (contraceptives, anti-depressants, analgesics EXCEPT aspirin, antihypertensives, and medications for osteoporosis and gastrointestinal diseases will be allowed).
Any metal in or on the body between the nose and the abdomen.
Any major organ system disease (by judgment of study medical team).
A glomerular filtration rate of 60 cc per minute or less. For the subjects that will receive Sildenafil as part of the study, additional exclusion criteria are as follows:
Nitroglycerin usage or nitrates (in addition to nitroglycerin) and use of phosphodiesterase 5 (PDE5) inhibitors within the previous 7 days of the study date.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Iowa — Iowa City, Iowa

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗